Here is a quick breakdown of where the key next-generation candidates currently stand: Retatrutide (Eli Lilly): Phase 3 trials are actively studying cardiovascular outcomes alongside weight loss
What Might Be Driving This Increased Risk
Importantly, these medications carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Your GP or diabetes specialist will work with you to find the most appropriate option based on your individual circumstances, including your blood glucose control, other health conditions, and personal preferences, in line with NICE guideline NG28 for type 2 diabetes in adults
Its also important to note that individual results can vary
Qualifying comorbidities include hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or dyslipidemia